Polycythemia Rubra Vera Basics To Brilliance: Haematology podcast

Basics to Brilliance: Haematology Podcast »

2M ago 1:12:33

Μοίρασέ το

Το περιεχόμενο παρέχεται από το Basics To Brilliance. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Basics To Brilliance ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

Polycythaemia- red cell #
Erythrocytosis – in red cell mass
Absolute Erythrocytosis
- M: Hct >0.60 or >0.52 + RCM >25% of mean
- F: Hct >0.56 or >0.48 + RCM >25% of mean

Apparent Erythrocytosis
- Men: Hct >0.52 + normal RCM
- Women: Hct >0.48 + normal RCM

Relative erythrocytosis
-Normal RCM + Reduced plasma volume (pathological dehydration)

M>F
Median >60yo

2' PRV: treat underlying cause +/- venesection (higher hct threshold)

Classification of Absolute:
EPO dependent
- Appropriate: High altitude, chronic hypoxia, localised hypoxia, congenital
- Inappropriate: Tumors, EPO doping, Testosterone replacement, diabetic meds
EPO independent:
- Acquired: Primary PRV (low EPO level, feedback)
- Congential Polycythemia= mutations in EPO receptors

Inv:
- Tumor Hunt
- Hx + Exam: ?True vs. Apparent
- FBC, U+E, LFTs, Ca2+
- Blood film
- Ferritin: low in 1’ PRV
- EPO
- Imaging
- NB: Normal Hct + High Red Cell # + Low MCV + Low ferritin –> Masked PRV
- Molecular Testing:
JAK2 (V617F)(96-97%)...SAMURAI JACK=BLOODY)
EXXON 12 (3%)
Del (13q), Del (20q), Del (1q), Tris. 8/9
- *SV thrombus 50% chance MPN
- BMBx: Tri-lineage myeloid expansion
- Familial screen for congenital(young)

Sx of primary PRV:
- Arterial*+ Venous clot (splanchnic*)
- Hyperviscosity sx
- Splenic sx
- Gout

Indications for urgent venesection...Hyperviscosity sx

BSH diagnostic:
JAK2 Pos
- Hct M >0.52, F > 0.48. Or RCM >25% above baseline OR Splanchnic vein thrombus
- JAK2 positive
JAK2 Neg= A1-4 + either ≥ 1 A or 2 B’s
A1: Hct M >0.60, F > 0.56. Or RCM >25% above baseline
A2: No JAK2
A3: No 2' cause
A4: BMBx pos
A5: Palpable splenomegaly
A5: Acq. genetics in BM cells
B’s: Plt >450, Neut >10 (>12.5 in smokers), Radiological splenomegaly, Low EPO

Congenital testing

Risk Stratification:
- Thrombi..
ECLAP study
High Risk:>65 + prev clots
Low Risk: <65 + no prev clot
- Malignant Transformation to MF (5-15% in 10 years), AML (2% at 10 year) markers:
Splenomegaly, LDH, HVAF burden >50% at diagnosis

Management:
- Lifestyle...CV factors decrease
- Aspirin +PPI for all (after confirmed)- decrease CV events 60% (ECLAP)
- Venesection first line (?isovolemic)- sx***
CYTO-PV trial: Hct aim <0.45, make iron def.
400-450ml off
Weekly -> 3-4x/year
- If previous clots: Lifelong anticoag (w/out aspirin)
- NB: if plt>1000 (acq. VWF) bleeding risk, 1st cytoreduce

Cytoreduction: (once confirmed primary PRV)
- High risk
- Progressive Hepatosplenomegaly
- Plts >1500
- WCC >15
- Constitutional Sx
- Poor tolerance of venesection

1st line: (OHC then/or IFN)
OHC
- Risk: Macrocytosis, ulcers, SCC, Malignant transformation
NB: pregnancy
Peg IFN-A
Young + fertile
Lowers HVAF
PROUD PV study (2020)
Continuation PV study (2022)
SE: flu like sx, AI disease (*thyroid), mood disturbances

2nd line
Rux: JAK2i (works for EXXON)
RESPONSE + RESPONSE 2 trial
MAJIC PV study
SE: immunosuppression, skin cancer, wean dont stop

Older
Busulfan: 1 dose (w monitoring) vs intermittent
Risk: leuk transformation, pneumonitis**

Pregnancy: inc. DVT
OHC not safe (stop 3 months prior)
IFN 1st
Aspirin
Uterine Doppler from 20wks of gestation?flow
LMWH 6 wks postpartum

5 επεισόδια